



SPECIFIC DIAGNOSTICS Acquisition

April 12, 2022

PIONEERING DIAGNOSTICS



- This presentation contains information, assumptions and estimates that were used by the Company to determine its objectives on a reasonable basis. They are subject to change or modification due to economic, financial, medical and competitive uncertainties in markets addressed by bioMérieux. Further information regarding these assumptions, risks and estimates are described in the documents registered with the Autorité des Marchés Financiers.
- The forward-looking statements contained in this presentation apply only up to the date of the presentation. Accordingly, the Company cannot give any assurance as to whether it will achieve the objectives described in this presentation, and makes no commitment or undertaking to update or otherwise revise such information.
- This document does not constitute an offer to sell or an invitation or solicitation of an offer to subscribe for or purchase any securities, and this shall not form the basis for or be used for any such offer or invitation or other contract or engagement in any jurisdiction.

SPECIFIC DIAGNOSTICS - COMPANY HISTORY



- Based in San Jose, California
- 82 employees

2011 - Company Formed

2011 - First Smart Blood Culture NIH Grant 2015 - First NIH Rapid AST Grant Awarded

2019 - Private Equity Funding, Joined by bioMérieux

2020 - CE-IVD Registration for Specific Diagnostics Reveal Rapid AST System


2021 - Co-Distribution in Europe with bioMérieux

2022 - FDA Clinical Studies Underway

FAST DIAGNOSTICS HAVE A KEY ROLE TO PLAY IN **ANTIMICROBIAL STEWARDSHIP (AMS) & SEPSIS**

Antimicrobial Resistance (AMR): the Silent Pandemic

Sepsis: one of the most significant health complications that can result from any infection



8% PATIENT SURVIVAL RATE





Stewardship & Infection Prevention

are key measures to address AMR fight



Every hour of delay in giving appropriate antibiotics reduces the chance to survive

4

SPECIFIC REVEAL RAPID AST PROVIDES ACTIONABLE RESULTS FOR GRAM-NEGATIVE BACTERIA IN AN AVERAGE OF 5 HOURS

SPECIFIC REVEAL™ RAPID-AST






FAST FROM POSITIVE BLOOD CULTURE RESULTS IN AN AVERAGE 5H*

ACTIONABLE WIDE ANTIMICROBIAL COVERAGE FOR BLOODSTREAM GRAM NEGATIVE INFECTION

EASE OF USE

QUICK SAMPLE PREP <3mn MODULAR TO ADJUST THROUGHPUT AS NEEDED


AST TECHNOLOGY BASED ON SMALL MOLECULE SENSORS



SPECIFIC'S NOVEL AND PATENTED SMALL MOLECULE SENSOR ARRAY

Each sensor generates a colorimetric (color change) reaction to the metabolic volatiles (volatile organic compounds, VOCs) released by microorganisms during growth





Determination of MIC's

BIOMÉRIEUX

Closing expected in Q2 2022


SPECIFIC REVEAL™ RAPID-AST

KEY TERMS




- Acquisition price: **425M\$**, paid in cash and in shares
- Intend to offset the 1% share dilution through a share buy back program post closing
- Revenue projection: > 60M\$ on year 5
- Dilutive on CEBIT for ~10 M€* in 2022 and ~15 M€* in 2023 due to product launch stage and R&D expenses, expected to become accretive from 2025*

THE ADDITION OF SPECIFIC REVEAL TO BIOMERIEUX SEPSIS SOLUTION ALLOWS TO ADDRESS THE BLOOD CULTURE (BC) GRAM NEGATIVE MAJOR UNMET NEED WITH A UNIQUE RAPID WORKFLOW



THIS ACQUISITION STRENGTHENS BIOMÉRIEUX LEADERSHIP IN MICROBIOLOGY OFFERING BEST IN CLASS SOLUTION & ADDRESSING KEY CLINICAL UNMET NEEDS



PIONEERING DIAGNOSTICS



